©2024 Stanford Medicine
Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
Recruiting
I'm InterestedTrial ID: NCT01721733
Purpose
The purpose of this study is to evaluate the effects of EPI-743 in children with Leigh
syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity
and mortality and disease associated biomarkers.
Official Title
A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Leigh Syndrome
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Clinical and MRI diagnosis of Leigh syndrome
- Moderate disease severity based on NPMDS score
- Age under 18 years
- Documented evidence of disease progression within 12 month of enrollment
- Availability of MRI that confirms necrotizing encephalopathy
- Patient or guardian able to consent and comply with protocol requirements
- Abstention from Coenzyme Q10, Vitamins C & E, lipoic acid and Idebenone
Exclusion Criteria:
- Allergy to EPI-743, Vitamin E or sesame oil
- History of bleeding abnormalities or abnormal PT/PTT
- Diagnosis of concurrent inborn error of metabolism
- Previous tracheostomy
- Ventilator dependent or use of noninvasive ventilatory support w/in 1 month of
enrollment
- LFTs greater than 2 times ULN
- Renal insufficiency
- End stage cardiac failure
- Fat malabsorption syndrome
- Use of anticoagulant medications
- Abstention from Botox for 6 months prior to enrollment and for duration of study
Intervention(s):
drug: Placebo
drug: EPI-743 15 mg/kg
drug: EPI-743 5 mg/kg
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Gregory Enns, MD
650-498-5798